Trajectories of disease-modifying therapies and associated sickness absence and disability pension among people with multiple sclerosis

被引：0
|
作者：
Teni, F. S. [1 ]
Machado, A. [1 ]
Murley, C. [1 ]
He, A. [2 ]
Fink, K. [2 ]
Gyllensten, H. [3 ]
Glaser, A. [2 ]
Alexanderson, K. [1 ]
Hillert, J. [2 ]
Friberg, E. [1 ]
机构：
[1] Karolinska Inst, Div Insurance Med, Dept Clin Neurosci, Stockholm, Sweden
[2] Karolinska Inst, Div Neurol, Dept Clin Neurosci, Stockholm, Sweden
[3] Univ Gothenburg, Inst Hlth & Care Sci, Sahlgrenska Acad, Gothenburg, Sweden
来源：
MULTIPLE SCLEROSIS JOURNAL | 2022年 / 28卷 / 3_SUPPL期
基金：
瑞典研究理事会;
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P770
引用
收藏
页码：672 / 673
页数：2
相关论文
共 50 条
  • [21] Current disease-modifying therapies in multiple sclerosis
    Kieseier, BC
    Hartung, HP
    SEMINARS IN NEUROLOGY, 2003, 23 (02) : 133 - 145
  • [22] Multiple sclerosis hospitalizations among users of oral disease-modifying therapies
    Nguyen, Thanh Phuong Pham
    Jacobs, Dina
    Thibault, Dylan
    Willis, Allison W.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 52
  • [23] Longitudinal changes in sickness absence and disability pension, and associations between disability pension and disease-specific and contextual factors and functioning, in people with multiple sclerosis
    Chruzander, Charlotte
    Tinghog, Petter
    Ytterberg, Charlotte
    Holmqvist, Lotta Widen
    Alexanderson, Kristina
    Hillert, Jan
    Johansson, Sverker
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2016, 367 : 319 - 325
  • [24] Factors Associated with Patient Preferences for Disease-Modifying Therapies in Multiple Sclerosis
    Hincapie, Ana L.
    Penm, Jonathan
    Burns, Craig F.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2017, 23 (08): : 822 - 830
  • [25] Self-employment, sickness absence, and disability pension in multiple sclerosis
    Machado, Alejandra
    Murley, Chantelle
    Hillert, Jan
    Alexanderson, Kristina
    Friberg, Emilie
    ACTA NEUROLOGICA SCANDINAVICA, 2022, 146 (03): : 283 - 294
  • [26] Predictors of relapses and disability progression after stopping disease-modifying therapies for multiple sclerosis
    Kister, I.
    Spelman, T.
    Patti, F.
    Duquette, P.
    Trojano, M.
    Izquierdo, G.
    Lugaresi, A.
    Grammond, P.
    Sola, P.
    Ferraro, D.
    Grand'Maison, F.
    Alroughani, R.
    Terzi, M.
    Boz, C.
    Hupperts, R.
    Lechner-Scott, J.
    Kapos, L.
    Pucci, E.
    Hodgkinson, S.
    Solaro, C.
    Butzkueven, H.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 356 - 357
  • [27] Economics of Multiple Sclerosis Disease-Modifying Therapies in the USA
    Daniel M. Hartung
    Current Neurology and Neuroscience Reports, 2021, 21
  • [28] Economics of Multiple Sclerosis Disease-Modifying Therapies in the USA
    Hartung, Daniel M.
    CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2021, 21 (07)
  • [29] Disease-modifying therapies in Chinese children with multiple sclerosis
    Yang, Fen
    Huang, De-hui
    Yang, Yang
    Wu, Wei-ping
    TURKISH JOURNAL OF PEDIATRICS, 2014, 56 (05) : 482 - 486
  • [30] Personalized Use of Disease-Modifying Therapies in Multiple Sclerosis
    Lee, Chi-Yan
    Chan, Koon-Ho
    PHARMACEUTICS, 2024, 16 (01)
12345